BioSpace News Archive

SciSparc Ltd. announced its board of directors authorized the Company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par value.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) approved the Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive 12-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR).

Blue Fin Group, a full-service management consulting firm to the pharmaceutical industry, today announced a new market research study video assessing current and future payer management in oncology by Kerri Fortier, Principal Consultant, and Jonny Clark, PharmD, Consultant.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Eye-related disorders are expanding at an accelerated pace across the globe.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Products and services offered by players in the global dental insurance market i.e. the dental insurance services is a health insurance specifically designed for the purpose of dental care.

Wilmington, Delaware, United States, Transparency Market Research Inc.: 3D printed drugs are medicines that are designed using 3D printing technology to customize them for patients in safe and effective manner.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global life sciences software market is expected to expand at a healthy rate from 2021 to 2031.

The rise in geriatric population and their vulnerability to various diseases increases hospital visits for proper check-up.

Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.